BioSpace News Archive

Emerald Health Therapeutics has received from Health Canada its cultivation license amendment and has full municipal permitting for its first of two 78,000 square foot greenhouses at its organic Metro Vancouver site in British Columbia.

Emerald Health Therapeutics announced that it has notified Pure Sunfarms Corp., its 50%-owned joint venture, that it does not agree that Emerald has any liability under the current Supply Agreement between Emerald and the Joint Venture with respect to the Joint Venture’s recent sales of cannabis to third parties at prices below the predetermined purchase price to Emerald set out in the Supply Agreement.

First patient enrolled in registration-directed Phase 2 clinical trial of RP1 in combination with Regeneron and Sanofi’s Libtayo® in CSCC

Celemics, provider of NGS target enrichment kits and innovative sequencing platforms, announced the release of a comprehensive NGS target enrichment workflow for clinical and translational research applications.

Anixa Biosciences, Inc., a biotechnology company focused on harnessing the body’s immune system in the fight against cancer, announced the appointment of Thomas Schlumpberger, Ph.D., as Executive Vice President, Diagnostics.

Hire Comes Just Weeks After Major Announcement with Greenleaf Health

In a prospective study, the addition of RNA genetic testing to hereditary cancer panels identified more disease-causing mutations in patients compared to DNA-only testing and clarified inconclusive results.

Gencove, the leading low-pass genome sequencing technology provider, announced today the launch of the first enterprise-ready low-pass sequencing analysis platform.

New Long-Term “Process A” Data from the Phase 1/2 EUROFANCOLEN Trial of RP-L102 to be Featured in Oral Session

Experienced Industry Executives to Lead Clinical Research and Regulatory Affairs with the Appointments of James Wooldridge, MD, as Chief Medical Officer and Steven Hamburger, PhD, as Vice President of Regulatory Affairs